Journal article · 2014 · Open access

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

Toni Michel Brand, Mari Iida, Emily Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David T. Yang, Kari Braun Wisinski, Ravi Salgia, Deric L. Wheeler

Molecular Cancer Therapeutics, 13(5), 1356–1368 · Published 1 May 2014 · DOI 10.1158/1535-7163.mct-13-1021

Open full textView at the publisherCite this paper

In brief

“Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer” is a 2014 journal article by Toni Michel Brand and 10 co-authors, published in Molecular Cancer Therapeutics. OpenAlex counts 67 citations as of 21 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
67
Most cited in
2018 (8)
Field-weighted impact
3.88
References
45
Authors
11

Abstract

Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high percentage of TNBCs overexpresses the EGF receptor (EGFR), yet EGFR inhibition has yielded little clinical benefit. Over the last decade, advances in EGFR biology have established that EGFR functions in two distinct signaling pathways: (i) classical membrane-bound signaling and (ii) nuclear signaling. Previous studies have demonstrated that nuclear EGFR (nEGFR) can enhance resistance to anti-EGFR therapies and is correlated with poor overall survival in breast cancer. On the basis of these findings, we hypothesized that nEGFR may promote intrinsic resistance to cetuximab in TNBC. To examine this question, a battery of TNBC cell lines and human tumors were screened and found to express nEGFR. Knockdown of EGFR expression demonstrated that TNBC cell lines retained dependency on EGFR for proliferation, yet all cell lines were resistant to cetuximab. Furthermore, Src Family Kinases (SFKs) influenced nEGFR translocation in TNBC cell lines and in vivo tumor models, where inhibition of SFK activity led to potent reductions in nEGFR expression. Inhibition of nEGFR translocation led to a subsequent accumulation of EGFR on the plasma membrane, which greatly enhanced sensitivity of TNBC cells to cetuximab. Collectively, these data suggest that targeting both the nEGFR signaling pathway, through the inhibition of its nuclear transport, and the classical EGFR signaling pathway with cetuximab may be a viable approach for the treatment of patients with TNBC.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Brand, T. M., Iida, M., Dunn, E., Luthar, N., Kostopoulos, K. T., Corrigan, K. L., Wleklinski, M. J., Yang, D. T., Wisinski, K. B., Salgia, R., & Wheeler, D. L. (2014). Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 13(5), 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021

MLA 9

Brand, Toni Michel, et al. “Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics, vol. 13, no. 5, 2014, pp. 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021.

Chicago

Brand, Toni Michel, Mari Iida, Emily Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, et al. 2014. “Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics 13 (5): 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021.

Harvard

Brand, T. M. et al. (2014) ‘Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer’, Molecular Cancer Therapeutics, 13(5), pp. 1356–1368. doi:10.1158/1535-7163.mct-13-1021.

IEEE

T. M. Brand et al., “Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer,” Molecular Cancer Therapeutics, vol. 13, no. 5, pp. 1356–1368, 2014, doi: 10.1158/1535-7163.mct-13-1021.

BibTeX

@article{brand2014nuclear,
  title     = {{Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer}},
  author    = {Brand, Toni Michel and Iida, Mari and Dunn, Emily and Luthar, Neha and Kostopoulos, Kellie T. and Corrigan, Kelsey L. and Wleklinski, Matthew J. and Yang, David T. and Wisinski, Kari Braun and Salgia, Ravi and Wheeler, Deric L.},
  journal   = {Molecular Cancer Therapeutics},
  year      = {2014},
  volume    = {13},
  number    = {5},
  pages     = {1356--1368},
  doi       = {10.1158/1535-7163.mct-13-1021},
  url       = {https://doi.org/10.1158/1535-7163.mct-13-1021}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201777
201888
201966
202066
202166
202222
202366
202455
202511
202611

Its field-weighted citation impact is 3.88: it has been cited 3.88 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research

  • triple-negative breast cancer
  • nuclear EGFR
  • EGFR signaling
  • cetuximab resistance
  • Src family kinases
  • nuclear translocation
  • EGFR knockdown
  • anti-EGFR therapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Brand, T. M., Iida, M., Dunn, E., Luthar, N., Kostopoulos, K. T., Corrigan, K. L., Wleklinski, M. J., Yang, D. T., Wisinski, K. B., Salgia, R., & Wheeler, D. L. (2014). Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 13(5), 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021

How many times has this paper been cited?

67 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Toni Michel Brand, Mari Iida, Emily Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David T. Yang, Kari Braun Wisinski, Ravi Salgia, Deric L. Wheeler.

What is the DOI of this paper?

10.1158/1535-7163.mct-13-1021, permanently at https://doi.org/10.1158/1535-7163.mct-13-1021. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.